Literature DB >> 24643795

Determining breast cancer axillary surgery within the surveillance epidemiology and end results-Medicare database.

Ryan K Schmocker1, Holly Caretta-Weyer, Jennifer M Weiss, Katie Ronk, Jeffrey Havlena, Noelle K Loconte, Marquita Decker, Maureen A Smith, Caprice C Greenberg, Heather B Neuman.   

Abstract

BACKGROUND: Use of sentinel lymph node biopsy (SLNB) is under-reported by cancer registries' "Scope of Regional Lymph Node Surgery" variable. In 2011, the Surveillance Epidemiology and End Results (SEER) Program recommended against its use to determine extent of axillary surgery, leaving a gap in the utilization of claims data for breast cancer research. The objective was to develop an algorithm using SEER registry and claims data to classify extent of axillary surgery for breast cancer.
METHODS: We analyzed data for 24,534 breast cancer patients. CPT codes and number of examined lymph nodes classified the extent of axillary surgery. The final algorithm was validated by comparing the algorithm derived extent of axillary surgery to direct chart review for 100 breast cancer patients treated at our breast center.
RESULTS: Using the algorithm, 13% had no axillary surgery, 56% SLNB and 31% axillary lymph node dissection (ALND). SLNB was performed in 77% of node negative patients and ALND in 72% of node positive. In our validation study, concordance between algorithm and direct chart review was 97%.
CONCLUSIONS: Given recognized inaccuracies in cancer registries' "Scope of Regional Lymph Node Surgery" variable, these findings have high utility for health services researchers studying breast cancer treatment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  SEER-Medicare; axillary surgery; breast cancer

Mesh:

Year:  2014        PMID: 24643795      PMCID: PMC4227499          DOI: 10.1002/jso.23579

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Axillary lymph node count is lower after neoadjuvant chemotherapy.

Authors:  Heather Neuman; Lisa A Carey; David W Ollila; Chad Livasy; Benjamin F Calvo; Anthony A Meyer; Hong Jin Kim; Michael O Meyers; E Claire Dees; Fran A Collichio; Carolyn I Sartor; Dominic T Moore; Lynda R Sawyer; Jill Frank; Nancy Klauber-DeMore
Journal:  Am J Surg       Date:  2006-06       Impact factor: 2.565

3.  Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival.

Authors:  Teresa D Hill; Harry J Khamis; Jerzy E Tyczynski; Hans J Berkel
Journal:  Ann Epidemiol       Date:  2005-11       Impact factor: 3.797

4.  Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count.

Authors:  Julie Bélanger; Geneviève Soucy; Lucas Sidéris; Guy Leblanc; Pierre Drolet; Andrew Mitchell; Yves-Eugène Leclerc; Julie Beaudet; Michel-Pierre Dufresne; Pierre Dubé
Journal:  J Am Coll Surg       Date:  2008-04       Impact factor: 6.113

5.  Potential for cancer related health services research using a linked Medicare-tumor registry database.

Authors:  A L Potosky; G F Riley; J D Lubitz; R M Mentnech; L G Kessler
Journal:  Med Care       Date:  1993-08       Impact factor: 2.983

6.  Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.

Authors:  David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

7.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

  7 in total
  5 in total

1.  Prevalence and Consequences of Axillary Lymph Node Dissection in the Era of Sentinel Lymph Node Biopsy for Breast Cancer.

Authors:  Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

2.  Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis.

Authors:  Sarah B Bateni; Anders J Davidson; Mili Arora; Megan E Daly; Susan L Stewart; Richard J Bold; Robert J Canter; Candice A M Sauder
Journal:  Ann Surg Oncol       Date:  2019-02-13       Impact factor: 5.344

3.  Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ.

Authors:  Brigid K Killelea; Jessica B Long; Weixiong Dang; Sarah S Mougalian; Suzanne B Evans; Cary P Gross; Shi-Yi Wang
Journal:  Ann Surg Oncol       Date:  2018-03-07       Impact factor: 5.344

4.  Prognostic significance of further axillary dissection in breast cancer patients with micrometastases & the number of micrometastases: a SEER population-based analysis.

Authors:  Liu Ying-Ying; Yu Tian-Jian; Liu Guang-Yu
Journal:  Future Sci OA       Date:  2018-04-23

5.  Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ.

Authors:  Peiyin Hung; Shi-Yi Wang; Brigid K Killelea; Sarah S Mougalian; Suzanne B Evans; Tannaz Sedghi; Cary P Gross
Journal:  JNCI Cancer Spectr       Date:  2019-08-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.